Evidence map›Paper›PMID 30349527›Full record

ArticleFrontiers in immunology2018

Modulation of B Cells and Homing Marker on NK Cells Through Extracorporeal Photopheresis in Patients With Steroid-Refractory/Resistant Graft-Vs.-Host Disease Without Hampering Anti-viral/Anti-leukemic Effects.

Lei Wang, Ming Ni, Angela Hückelhoven-Krauss, Leopold Sellner, Jean-Marc Hoffmann, Brigitte Neuber, Thomas Luft, Ute Hegenbart, Stefan Schönland, Christian Kleist and 13 more

Registry-linked trialOpen access · goldAbstract read
In one paragraph

Article in Frontiers in immunology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06112951 (The Use of Extracorporeal Photopheresis as Immunomodulatory Therapy of Subclinical Antibody-mediated Rejection After Lung Transplantation), which is not on this map. Cited by 20 papers.

0numbers the graph read from it
0cells of the map it votes in
20citing papers in PubMed
1.6field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT06112951 narecruitingnot on this mapstarted 2024, after this paper: background citation

The Use of Extracorporeal Photopheresis as Immunomodulatory Therapy of Subclinical Antibody-mediated Rejection After Lung Transplantation: a Prospective RCT

TypeinterventionalSponsorMedical University of ViennaRan2024 to 2027Enrolled80ConditionsAntibody-mediated Rejection, Lung Transplant RejectionArmsExtracorporeal Photopheresis
3 · Its place in the literature

Who cites it

20 citing papers in PubMed, 30 citations in OpenAlex.

  1. Extracorporeal photopheresis-New insights into an old procedure.Transfusion medicine (Oxford, England) · 2026
    Trial
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Graft-Versus-Host Disease Mouse Models: A Clinical-Translational Perspective.Methods in molecular biology (Clifton, N.J.) · 2025
    Review
  9. Article
  10. Article
  11. Article
  12. Review
  13. Review
  14. Review
  15. Review
  16. European dermatology forum - updated guidelines on the use of extracorporeal photopheresis 2020 - part 1.Journal of the European Academy of Dermatology and Venereology : JEADV · 2020
    Article
  17. Review
  18. Review
  19. Article
  20. Shaping of CD56Frontiers in immunology · 2019
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

23 authors at 7 institutions in 3 countries.

Lei WangDepartment of Internal Medicine V, University Clinic Heidelberg, Heidelberg, Germany.
Ming NiDepartment of Internal Medicine V, University Clinic Heidelberg, Heidelberg, Germany.
Angela Hückelhoven-KraussDepartment of Internal Medicine V, University Clinic Heidelberg, Heidelberg, Germany.
Leopold SellnerDepartment of Internal Medicine V, University Clinic Heidelberg, Heidelberg, Germany.
Jean-Marc HoffmannDepartment of Internal Medicine V, University Clinic Heidelberg, Heidelberg, Germany.
Brigitte NeuberDepartment of Internal Medicine V, University Clinic Heidelberg, Heidelberg, Germany.
Thomas LuftDepartment of Internal Medicine V, University Clinic Heidelberg, Heidelberg, Germany.
Ute HegenbartDepartment of Internal Medicine V, University Clinic Heidelberg, Heidelberg, Germany.
Stefan SchönlandDepartment of Internal Medicine V, University Clinic Heidelberg, Heidelberg, Germany.
Christian KleistDepartment of Nuclear Medicine, University Clinic Heidelberg, Heidelberg, Germany.
Martin SillDivision Biostatistics, German Cancer Research Center, Heidelberg, Germany.
Bao-An ChenDepartment of Hematology, Zhongda Hospital, Southeast University, Nanjing, China.
Patrick WuchterDepartment of Internal Medicine V, University Clinic Heidelberg, Heidelberg, Germany.
Volker EcksteinDepartment of Internal Medicine V, University Clinic Heidelberg, Heidelberg, Germany.
William KrügerDepartment of Internal Medicine C, Haematology, Oncology, Stem Cell Transplantation, Palliative Care, University Clinic Greifswald, Greifswald, Germany.
Inken HilgendorfDepartment of Internal Medicine II, University Clinic Jena, Jena, Germany.
Ronit YerushalmiHematology Division, Chaim Sheba Medical Center, Tel Hashomer, Israel.
Arnon NaglerHematology Division, Chaim Sheba Medical Center, Tel Hashomer, Israel.
Carsten Müller-TidowDepartment of Internal Medicine V, University Clinic Heidelberg, Heidelberg, Germany.
Anthony D HoDepartment of Internal Medicine V, University Clinic Heidelberg, Heidelberg, Germany.
Peter DregerDepartment of Internal Medicine V, University Clinic Heidelberg, Heidelberg, Germany.
Michael SchmittDepartment of Internal Medicine V, University Clinic Heidelberg, Heidelberg, Germany.
Anita SchmittDepartment of Internal Medicine V, University Clinic Heidelberg, Heidelberg, Germany.
University Hospital Heidelberg · DEHeidelberg University · DESheba Medical Center · ILGuiyang Medical University · CNJena University Hospital · DEUniversitätsmedizin Greifswald · DEZhongda Hospital Southeast University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Graft-vs.-host disease (GvHD), a severe complication of allogeneic hematopoietic stem cell transplantation, significantly affects the post-transplant morbidity and mortality. Systemic steroids remain the gold standard for the initial management of GvHD. However, up to 60% of patients will not sufficiently respond to steroids. Extracorporeal photopheresis (ECP), a cell-based immunotherapy, has shown good clinical results in such steroid-refractory/resistant GvHD patients. Given its immunomodulatory, but not global immunosuppressive and steroid-sparing capacity, ECP constitutes an attractive option. In the case of GvHD, the balance of immune cells is destroyed: effector cells are not any longer efficiently controlled by regulatory cells. ECP therapy may restore this balance. However, the precise mechanism and the impact of ECP on anti-viral/anti-leukemic function remain unclear. In this study, 839 ECP treatments were performed on patients with acute GvHD (aGvHD) and chronic GvHD (cGvHD). A comprehensive analysis of effector and regulatory cells in patients under ECP therapy included multi-parametric flow cytometry and tetramer staining, Luminex

Indexed as

AdultAgedB-LymphocytesCytokinesDrug ResistanceFemaleGraft vs Host DiseaseHumansKiller Cells, NaturalLeukemiaMaleMiddle AgedMyeloid-Derived Suppressor CellsPhotopheresisSteroidsTranscriptomeCytokinesSteroidsanti-leukemic effectanti-viral effectECPeffector cellsGvHDimmunomodulationproinflammatory cytokinesregulatory cells

Identifiers

PMID30349527
PMCPMC6186805
OpenAlexW2897429402

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.